Authors’ Reply to Standing et al.: “Effect of Age-Related Factors on the Pharmacokinetics of Lamotrigine and Potential Implications for Maintenance Dose Optimisation in Future Clinical Trials”
- 119 Downloads
The inclusion of elderly subjects does not lead to biasAlthough we acknowledge that the step function used to describe changes in the apparent total clearance of the drug from plasma after oral administration (CL/F) in patients > 65 years of age is arbitrary (i.e. the cut-off age was not estimated), the available pharmacokinetic data...
No external funding was used in the preparation of this reply.
Compliance with Ethical Standards
Conflict of interest
Oscar Della Pasqua is Senior Director Clinical Pharmacology at GlaxoSmithKline and owns GlaxoSmithKline shares. Sven C. van Dijkman, Nico C.B. de Jager, Willem M. Rauwé, and Meindert Danhof have no conflicts of interest directly relevant to the contents of this reply.
- 1.Standing JF, Anderson BJ, Hennig S, Holford NH, Johnston T, Knibbe CAJ, Lonsdale DO, Rostami-Hodjegan A. Comment on: effect of age-related factors on the pharmacokinetics of lamotrigine and potential implications for maintenance dose optimisation in future clinical trials. Clin Pharmacokinet 2018. https://doi.org/10.1007/s40262-018-0697-7.CrossRefPubMedGoogle Scholar
- 10.Vauzelle-Kervroëdan FL, Rey E, Cieuta C, Pariente-Khayat A, Pons G, d’Athis P, Bidault R, Dulac O, Olive G. Influence of concurrent antiepileptic medication on the pharmacokinetics of lamotrigine as add-on therapy in epileptic children. Br J Clin Pharmacol. 1996;41(4):325–30.CrossRefPubMedPubMedCentralGoogle Scholar